The cohesin-interacting protein, precocious dissociation of sisters 5A/sister chromatid cohesion protein 112, is up-regulated in human astrocytic tumors

CARSTEN HAGEMANN1, BETTINA WEIGELIN1, STEPHAN SCHOMMER1, MARKUS SCHULZE1, NAIF AL-JOMAH2, JELENA ANACKER3, STEFANIE GERNGRAS1, SIGLINDA KÜHNEL1, ALMUTH F. KESSLER1, BÜLENT POLAT4, RALF-INGO ERNEUSTUS1, RAJNIKANT PATEL2 and GILES H. VINCE1

1Tumorbiology Laboratory, Department of Neurosurgery, University of Würzburg, Josef-Schneider-Str. 11, D-97080 Würzburg, Germany; 2Department of Biochemistry, Henry Wellcome Building, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK; 3Department of Obstetrics and Gynaecology, University of Würzburg, Josef-Schneider-Str. 4; 4Department of Radiation Oncology, University of Würzburg, Josef-Schneider-Str. 11, D-97080 Würzburg, Germany

Received June 21, 2010; Accepted August 26, 2010

DOI: 10.3892/ijmm.2010.551

Abstract. Glioblastoma multiforme (GBM) is the most prevalent, highly malignant, invasive and difficult-to-treat primary brain tumor in adults. At the genetic level, it is characterized by a high degree of chromosomal instability and aneuploidy. It has been shown that defects in the mitotic spindle checkpoint could lead to the development of aneuploidy as well as tumorigenesis. Additional proteins regulating sister chromatid cohesion could also be involved in maintaining the fidelity of chromosome segregation. One such protein is the precocious dissociation of sisters 5A (Pds5A), also known as sister chromatid cohesion protein 112. It is a nuclear protein, expressed from the S right through to the mitotic phase. It is highly conserved from yeast to man and plays a role in the establishment, maintenance and dissolution of sister chromatid cohesion. The mutation of Pds5A orthologs in lower organisms results in chromosome missegregation, aneuploidy and DNA repair defects. It is considered that such defects can cause either cell death or contribute to the development of cancer cells. Indeed, altered expression levels of Pds5A have been observed in tumors of the breast, kidney, oesophagus, stomach, liver and colon. Malignant gliomas, however, have not been analysed so far. Herein, we report on the cloning of Rattus norvegicus Pds5A and on the analysis of its expression pattern in rat tissue. We also show that Pds5A is significantly overexpressed at both the mRNA and protein level and that this overexpression correlates positively with the WHO grade of human gliomas. However, functional assays show that the siRNA-mediated knockdown of Pds5A affects sister chromatid cohesion but does not influence mitotic checkpoint function or the proliferation and survival of GBM cells. Although the mechanism by which Pds5A functions in GBM cells remains unclear, its overexpression in high grade gliomas implies that it could play a pivotal role during the development and progression of astrocytic tumors.

Introduction

Chromosomal instability and aneuploidy, the gain and loss of chromosomes, is a characteristic of most malignant cells that is seen during the early stages of tumor development (1,2). It is thought that such alterations lead to the deregulation of the signalling network within the cells with the loss of tumor suppressor genes and the overexpression of oncogenes that drive tumorigenesis (3-7). Usually, the mitotic spindle checkpoint ensures the fidelity of sister chromatid segregation during mitosis by delaying the onset of anaphase until the kinetochores of all the chromosomes have attached to the spindle microtubules (8,9). It has been shown that the expression of spindle checkpoint proteins (e.g. Bub1, BubR1, Mad2A) is altered in human malignancies (8,10-12), and in animal models, such changes lead to an increased susceptibility to tumor induction by chemicals and carcinogens (13,14) or even directly cause cancer development (15,16). A defective spindle checkpoint is also the cause of the human chromosomal instability syndrome, which is characterized by premature chromatid separation and mosaic variegated aneuploidy (17-20). These patients do not only suffer from severe developmental defects, but are also very prone to cancer development (21,22).
The protein precocious dissociation of sisters 5 (Pds5), which is also known as sister chromatid cohesion protein 112 (SCC-112) (Table I), is a nuclear protein expressed from the S right through to the mitotic phase, at the time when sister chromatid cohesion exists (23-26). It is highly conserved from yeast to man (Table I) and interacts with the cohesin protein complex, although it is not a cohesin subunit itself (23,24,27-30). Cohesin forms a ring-like structure and holds sister chromatids together until spindle fibers attach to the kinetochores (9,31-33). Anaphase is initiated by the proteolysis of the cohesin subunit, SCC-1, by an endopeptidase called separase (32,33). Cohesin is dissolved, and the sister chromatids are released and distributed equally between the daughter cells by the mitotic spindle (9,31). Our understanding of the mechanism of sister chromatid cohesion and segregation has largely been derived from experiments on the budding yeast, *Saccharomyces cerevisiae* (32,33). In fission yeast and vertebrate cells, separase plays a less important role in sister chromatid separation and it is thought that other mechanisms could regulate chromatid segregation in these cell types (30). It has been shown that Pds5 could be involved in the establishment, maintenance and dissolution of cohesion in both yeasts and humans (27-30,34,35). It could also be implicated in embryonic development (36). The structure of *S. cerevisiae* Pds5p contains ~26 HEAT repeats suggesting that it could act as a scaffold protein with numerous sites for binding the globular domains of other proteins (27). Nonetheless, the detailed mechanism of its function remains unresolved.

The homologous recombination repair of DNA double strand breaks (DSB) is dependent on sister chromatid cohesion, as the intact sister chromatid paired to the damaged chromatid, serves as the repair template (37) and this DSB-repair is defective if Pds5 is not present during meiosis in *S. cerevisiae* (38). The mutants of BimD and Spo76, the orthologs of Pds5 in *Aspergillus nidulans* and *Sordaria macrospora* respectively, are hypersensitive after exposure to DNA damaging agents (39,40) and in the fission yeast, *Schizosaccharomyces pombe*, Pds5 is required for both cell survival following DNA damage and for accurate chromosome segregation (41). In human cells, Pds5 is involved in stabilizing replication forks and the disturbance of this mechanism leads to the spontaneous appearance of DNA damage (42,43). Therefore, defects in Pds5 expression not only result in chromosome missegregation and aneuploidy, but also in DNA repair defects and this could cause the death and oncogenesis of mitotic cells. Indeed, the overexpression of the human ortholog of Pds5A in *Cos1* and MDA-MB231 breast cancer cells, led to apoptotic cell death as was shown by an increase in the number of cells in the sub-G1 phase and the enhanced activation of caspase-3 (25). In addition, the down-regulation of Pds5A mRNA was observed in both breast and kidney tumor samples when compared to the corresponding normal tissues (25), whereas another study reported the up-regulation of Pds5A mRNA and protein levels in tumors of the oesophagus, stomach, liver and transverse colon (26). The overexpression of Pds5A in 293T cells and 3 nasopharyngeal epithelial cell lines (NP69, CNE-2 and C666-1) led to increased colony formation and a higher growth rate, whereas the expression of Pds5A siRNA had the opposite effect (26). Together, these data suggest that Pds5A could have tissue-specific and bifunctional roles in tumorigenesis, showing either tumor suppressor activity or promoting cell proliferation, depending on the cell- and tissue-type (26).

Currently, there are no data concerning Pds5A expression in human astrocytic tumors that display a high level of aneuploidy during their early stages of development (5,44,45). Diffuse astrocytomas WHO grade II (low grade astrocytomas, LGAs) are well differentiated tumors with diffuse infiltration of the adjacent brain parenchyma (46). Most of these tumors progress to anaplastic astrocytomas WHO grade III or glioblastoma multiforme (GBM) within 4-5 years after diagnosis (47). GBM is the most prevalent, highly malignant, invasive and difficult-to-treat primary brain tumor in adults. The treatment regimen of patients with GBM includes neurosurgical tumor resection followed by local γ-irradiation and chemotherapy (46). However, in spite of multidisciplinary treatment the median survival is 14.6 months (48). Therefore, it is vital to identify new potential therapeutic targets for future small molecule therapies. Targeting factors involved in the regulation of DNA damage response, mitosis and their cell cycle checkpoints could be a good strategy to prevent the progression of LGAs to high grade malignancies. Pds5A could be a candidate for such treatment options.

Here, we report on the cloning of *Rattus norvegicus* Pds5A from pheochromocytoma PC12 cells, the expression pattern of Pds5A in different rat tissues and on the overexpression of Pds5A at both the mRNA and protein level, which correlates with the WHO grade of human gliomas. In addition, we examined the potential role of Pds5A in the mitotic checkpoint, sister chromatid cohesion and the proliferation and survival of GBM cells.

**Materials and methods**

Cloning of full-length rat Pds5A. Total RNA was extracted from rat pheochromocytoma PC12 cells using the SV total RNA isolation kit (Promega, Mannheim, Germany) and mRNA was enriched with the Oligotex® mRNA mini kit (Qiagen, Hilden, Germany). The RevertAid™ first strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany) was used to generate the cDNA. The cDNA for *Rattus norvegicus* Pds5A was cloned by the PCR amplification of 3 overlapping fragments using the primers 5'-CCC GGG ATC CCA GGA TGG ACT TCA CGC A-3' (forward) and 5'-GAT ATC GTT CAT CAG TTT CAC TAG TG-3' (reverse) for the N-terminal fragment 1 (1917 bp), 5'-CAC TAG TGA AAC TGA TGA CAT CAG TTT CAC TAG TG-3' (reverse) for the middle part (fragment 2, 1690 bp) and 5'-CTC GAG TCT GAT GCC TCT GAA TGG ACT TCA CGC A-3' (forward) and 5'-AAT CTC TGG AGG TTT GGC CTT CAT TTT CTC C-3' (reverse) for the C-terminal fragment 3 (633 bp). Thermocycle parameters were as follows: Five minutes at 94°C, 32 cycles of 30 sec at 94°C, 30 sec at 56°C (5°C for fragment 1), 1 min at 72°C and 10 min at 72°C. The amplification products were purified using the Nucleo Spin® Extract II kit (Macherey-Nagel, Düren, Germany) and cloned into the pGEMT®-Easy Vector (Promega) following the manufacturer’s instructions. The full-length Pds5A cDNA sequence was determined by extended hotshot sequencing (Seqlab, Göttingen, Germany).
Tissue samples. Tumor biopsies were obtained from patients treated at the University Hospital of Würzburg. Informed consent was obtained from the patients for the acquisition of tumor material and the study was approved by the local ethics committee. The GBM patients underwent surgical tumor resection followed by radiotherapy and temozolomide chemotherapy, except for GBM samples 2369 and 2423. These were from recurring tumors pre-treated with γ-irradiation and chemotherapy. The human brain tumors were classified by routine histology based on the WHO criteria (49). Temporal brain tissue samples (normal brain, NB) came from patients with epilepsy (kindly provided by Thomas Freiman, at the University Hospital of Freiburg im Breisgau, Germany). Details about patient gender, age, diagnosis, location of tumor and treatment regimen have been described previously (50). Organs for expression studies were taken from Sprague-Dawley rats (Harlan Winkelmann, Borchen, Germany). Immediately after removal all tissue samples were frozen at -80°C and then stored in liquid nitrogen.

Cells and cell culture. The human GBM cell lines, U87, U251, U343 and U373, were originally purchased from the American Type Culture Collection (Rockville, MD), and GaMG was established from a patient with GBM (Gade Institute of the University of Bergen, Norway) (51). Cell lines were grown as previously described (52) in 75 cm² flasks (Corning, NY) at 37°C in an atmosphere of 5% CO₂ and 100% humidity.

siRNA transfection. Cells were transfected by nucleofection (Lonza, Cologne, Germany) as previously described (52, 53). Pds5A specific siRNA 5'-CAGCGAUGUUGGUUAGUGATT-3' was synthesized by Qiagen. siRNA (2 μM or 750 nM) was used per transfection, as indicated. Transfected cells were transferred to 6-well plates and incubated for 24 h or more, as previously described. For chromosome spreading assays, a SMARTpool of 4 Pds5A oligonucleotides (5'-GAUAAACGGUGGCGAGUAA-3', 5'-CCAAUAAAGAUGUGCUCU-3', 5'-GAACAGCAUUGACGACAAA-3' and 5'-GAGAGAAAUAGCCCGGAAA-3') and non-targeting, control siRNA oligonucleotides were purchased from Thermo Scientific (CO, USA). The siRNA oligonucleotides were dissolved in RNase-free buffer (20 mM KCl, 6 mM Hepes, 0.2 mM MgCl₂, pH 7.5) at a concentration of 20 μM. Cells were transfected with the siRNA oligonucleotides using Interferin reagent (BioScience Autogen, Nottingham, UK) following the manufacturer's instructions.

RNA and protein extraction. Trypsinised cells were washed twice with phosphate-buffered saline (PBS) and then resuspended in 50 μl PBS. Total mRNA and protein were purified from these cells and from 30 mg of tissue samples by the Nucleo-Spin RNA/Protein Kit (Macherey-Nagel) following the manufacturer's instructions and as previously described (50). Purified RNA samples were stored at -80°C. Proteins were solubilized in 100 μl protein loading buffer containing 50 mM Tris (2-carboxyethyl) phosphine hydrochloride reducing agent. These mixtures were stored at -20°C.

Semiquantitative RT-PCR analysis. Semiquantitative RT-PCR was performed as described previously (50). The amount

<table>
<thead>
<tr>
<th>Name</th>
<th>Accession (protein)</th>
<th>Alternate names</th>
<th>Species</th>
<th>Size (amino acids)</th>
<th>Identity (%)</th>
<th>Protein identities were calculated using the program, BLAST 2 Sequences (<a href="http://www.ncbi.nlm.nih.gov/blast2-seq/blast2-seq.shtml">www.ncbi.nlm.nih.gov/blast2-seq/blast2-seq.shtml</a>), using standard settings.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pds5p</td>
<td>NP_013790</td>
<td>Saccharomyces cerevisiae</td>
<td>1277</td>
<td>25</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>BAB17084</td>
<td>Schizosaccharomyces pombe</td>
<td>1285</td>
<td>24</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Spo76</td>
<td>CAB51808</td>
<td>Aspergillus nidulans</td>
<td>1596</td>
<td>26</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>AA003863</td>
<td>Sordaria macrospora</td>
<td>1596</td>
<td>26</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Pds5B</td>
<td>NP_510719</td>
<td>Drosophila melanogaster</td>
<td>1218</td>
<td>21</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>AA97865</td>
<td>Caenorhabditis elegans</td>
<td>1570</td>
<td>18</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>AA94283</td>
<td>Xenopus laevis</td>
<td>1323</td>
<td>18</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>ABO00955</td>
<td>Rattus norvegicus</td>
<td>1333</td>
<td>19</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Pds5B</td>
<td>NP_001093899</td>
<td>Homo sapiens</td>
<td>1337</td>
<td>19</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Pds5A</td>
<td>NP_055647</td>
<td>Homo sapiens</td>
<td>1447</td>
<td>19</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Protein identities were calculated using the program, BLAST 2 Sequences (www.ncbi.nlm.nih.gov/blast2-seq/blast2-seq.shtml), using standard settings.
Immunohistochemistry. GBM sections (2 μm) were cut from the immunodetection system (Amersham Pharmacia Biotech). Blots were developed in the darkroom using the ECL-Plus method (GE Healthcare, Braunschweig, Germany), both diluted 1:1000 in TBST. Radish peroxidase (HRP) conjugated secondary antibodies: Anti-β-tubulin primary antibody (Sigma, Deisenhofen, Germany) was used at a dilution of 1:1000. Pds5A protein expression was visualized using the streptavidin-biotin system (Dako, Glostrup, Denmark). Proteins were blotted to a nitrocellulose membrane (Schleicher & Schüll, Dassel, Germany). After blocking in 5% milk powder, the membrane was incubated with rabbit polyclonal anti-SCC-112 antibody (Bethyl Laboratories Inc., Montgomery, TX, USA) and diluted 1:500 in TBST [50 mM Tris Base, 150 mM NaCl, 0.1% (v/v) Tween-20] containing 5% milk powder. Mouse monoclonal anti-γ-tubulin primary antibody (Sigma, Deisenhofen, Germany) was used at a dilution of 1:5000 in TBST. Rabbit polyclonal cleaved caspase-3 antibody (Cell Signaling, Danvers, MA, USA) was used at a dilution of 1:1000. After washing in TBST, the membrane was incubated with horse-radish peroxidase (HRP) conjugated secondary antibodies: Goat anti-rabbit IgG HRP (Santa Cruz, CA, USA) or sheep anti-mouse IgG HRP (Amersham Pharmacia Biotech, Braunshweig, Germany), both diluted 1:1000 in TBST. Blots were developed in the darkroom using the ECL-immunodetection system (Amersham Pharmacia Biotech).

Western blotting. The expression of Pds5A protein in the GBM cell lines and human tumor biopsies was determined by Western blotting as described previously (54) using NuPAGE® 3-8% Tris-acetate polyacrylamide gels (Invitrogen, Heidelberg, Germany). Proteins were blotted to a nitrocellulose membrane (Schleicher & Schüll, Dassel, Germany). After blocking in 5% milk powder, the membrane was incubated with rabbit polyclonal anti-SCC-112 antibody (Bethyl Laboratories Inc., Montgomery, TX, USA) and diluted 1:5000 in TBST. Goat anti-rabbit IgG HRP (Santa Cruz, CA, USA) or sheep anti-mouse IgG HRP (Amersham Pharmacia Biotech, Braunshweig, Germany), both diluted 1:1000 in TBST. Blots were developed in the darkroom using the ECL-immunodetection system (Amersham Pharmacia Biotech).

FACS analysis. U251 cells were transfected with 2 μM Pds5A siRNA as described above. The medium was changed 72 h later, and 25 ng/ml nocodazole were added to interfere with spindle formation and the induction of the mitotic checkpoint. After 24-h incubation floating cells from the medium were harvested by centrifugation at 230 x g and adherent cells by trypsinisation. Both cell populations were combined, washed once with PBS and finally resuspended in 500 μl PBS. The cells were then fixed in ethanol and stained with propidium iodide (Sigma). Analysis of the DNA content was performed by flow cytometry (FACSCalibur, Becton-Dickinson, Franklin Lakes, NJ, USA).

Proliferation assay. U251 cells (5x10⁴) were transfected with 750 nM Pds5A siRNA as described above and equally distributed to six 60-mm petri-dishes (Coming), filled with 3 ml medium each. The cells were then harvested at 24, 48, 72, 96, 120 and 144 h by trypsinisation and counted using a Fuchs-Rosenthal chamber. The fold increase in cell number was calculated to establish growth curves.

Apoptosis assay. The U251 and GaMG cells were transfected with 2 μM Pds5A siRNA as described above and incubated for 72 h, before the medium was replaced by medium containing DMSO, 50 μM cisplatin, 100 ng/ml nocodazole or 1 μg/ml staurosporine (all from Sigma). The cells were harvested 24 h later and analysed for the presence of cleaved caspase-3 by Western blotting as described above.

Chromosome spreads. U251 cells were transfected with either Pds5A siRNA or control siRNA and 48 h post-transfection the cells were treated with either taxol (1 μM for 24 h) or with a mixture of taxol (1 μM) and okadaic acid (1 μM) for 12 h. Chromosome spreads from the U251 cells were then prepared as follows: Cells were harvested by mitotic shake-off and swollen in hypotonic sodium chloride (75 mM) for 25 min at 37°C. The cells were then centrifuged (1000 rpm for 10 min) and resuspended in Carnoy’s solution (75% methanol, 25% acetic acid) for 10 min, with 3 changes in fixation. For spreading, cells in Carnoy’s solution were dropped onto glass slides and dried at 37°C. The slides were stained with 4% Giemsa (Merck, Nottingham, UK) in phosphate buffer at pH 6.8 for 7 min, washed briefly in deionised water and air dried. The chromosome spreads were viewed on a Nikon inverted microscope (TE3000; Tokyo, Japan), using a 100x objective (Plan Apochromat, NA 1.4) and the images were captured using an Orca ER charge-coupled device camera (Hamamatsu Photonics, Bridgewater, NJ, USA). The images were processed using Photoshop (Adobe Systems Inc., CA, USA). When the images were quantified ~100 chromosome spreads were analysed.

Statistical analysis. The DNA and protein band intensity was quantified by densitometry using the BioDocAnalyze software (Biometra, Göttingen, Germany). The DNA bands were normalised with respect to the combined expression of GAPDH and β-actin and the protein expression was normalised to the respective γ-tubulin expression. Box-plots were generated and statistical analysis was performed using GraphPad Prism 4 Software (GraphPad Software Inc., San Diego, CA, USA). Statistical significance was defined by two-tailed t-tests and analysis of variance (ANOVA). A value of...
p<0.05 was considered to be significant. All functional assays were analysed using the software R 2.9.2 (The R Foundation for Statistical Computing), including the package Rcmdr. Statistical methods used were ANOVA, linear modelling, generalised linear modelling and two-tailed t-tests. A value of \( p < 0.05 \) was considered to be significant.

**Results**

**Cloning of Pds5A cDNA from Rattus norvegicus and its expression pattern in rat tissue.** Even though the human Pds5A sequence had been published (24, 25, 29), only a predicted 3621 bp sequence of the rat homologue was available from the NCBI GenBank (XM_223406). Based on this sequence, we started cloning of the full-length cDNA sequence of Pds5A from the rat pheochromocytoma cell line, PC12. In contrast to the predicted sequence we found an extended coding region as a result of a shift in the boundary between exons 30 and 31. This shift causes a frameshift mutation, removing the originally predicted stop codon in exon 31. Therefore, Pds5A from *Rattus norvegicus* consists of 31 exons and comprises of 4001 bp (including start and stop codons). The full-length coding sequence has been deposited at NCBI GenBank (EF460313). Table I summarises the information and protein sequence identities for *S. cerevisiae* Pds5p, *Schizosaccharomyces pombe* Pds5+, *Aspergillus nidulans* BimD, *Sordaria macrospora* Spo76, *Drosophila melanogaster* Pds5, *Caenorhabditis elegans* Evt-14, *Rattus norvegicus* Pds5A and Pds5B (APRIN). The proteins are highly conserved during evolution and share a high degree of amino acid identity in a range from 19% between the budding yeast, Pds5p, to 97% for Pds5A from the rat, when compared to the human Pds5A (Table I).

In order to determine the mRNA expression pattern of Pds5A, we screened different organs from Sprague-Dawley rats by semiquantitative RT-PCR (Fig. 1). Pds5A was expressed by all the organs tested (Fig. 1a). Whereas the heart, skeletal muscle and cerebellum displayed low mRNA expression, the brain and peripheral organs showed higher expression levels. The expression levels were normalised to that of the housekeeping gene GAPDH, which was used as the internal loading control. Figure 1 shows the median ± SD of organs from 3 animals.

---

**Figure 1.** Expression analysis of Pds5A mRNA in 9 rat organs and C6 GBM cells. (a) Total RNA from the organs indicated and from a C6 rat glioblastoma cell line was used as the template for semiquantitative RT-PCR analysis. Primers, specific for Pds5A, were designed in flanking exons. For the negative control cDNA was excluded from the PCR reaction (-). The various cDNA concentrations were normalized to that of the housekeeping gene GAPDH, which was used as the internal loading control. The result shown is from the organs of a representative animal out of 3 animals analysed. (b) Comparison of densitometrically quantified Pds5A mRNA expression. Each value was normalised to the respective GAPDH mRNA. Shown is the median ± SD of organs from 3 animals.

**Figure 2.** Western blot analysis of Pds5A protein expression by human glioblastoma cell lines. Protein lysates were isolated from U87, U251, U343, U373 and GaMG human glioblastoma cells and separated by polyacrylamide gel electrophoresis. The expressed Pds5A protein was visualized using a polyclonal Pds5A antibody. \( \gamma \)-tubulin served as the loading control.
Figure 3. Expression analysis of Pds5A in NB and human astrocytic tumor samples by semiquantitative RT-PCR. (a) Total RNA from NB, LGA and GBM tissue samples was used as the template for RT-PCR analysis. Primers, specific for Pds5A, were designed in flanking exons. Genomic DNA from HBMEC cells was used as the positive control (+). For the negative control, cDNA was excluded from the PCR reaction (-). The various cDNA concentrations were normalised to that of the housekeeping gene, ß-actin, which was used as the internal loading control. The size (bp) of the cDNAs is indicated on the right. The numbers refer to the tumor samples used (50). (b) Box-plot analysis of densitometrically quantified Pds5A mRNA expression. The black line within the boxes represents the median expression, boxes show the quartiles and bars indicate minimum and maximum values. ANOVA analysis revealed a statistically significant increase of mRNA expression (p=0.0009). (c) Percentage of tissue samples expressing Pds5A mRNA. Light grey represents samples with weak expression of Pds5A mRNA (>0 but <50 on a scale from 0 (no expression detectable) to 100 (strongest expression of Pds5A, tumor 2329)) and black shows strong expression (≥50).

Figure 4. Western blot analysis of Pds5A protein expression in human astrocytic tumor samples. (a) Protein lysates were isolated from LGA and GBM tissue samples and separated by polyacrylamide gel electrophoresis. The expressed Pds5A protein was visualized using a polyclonal SCC-112 antibody. The numbers refer to the tumor samples used (50). ß-tubulin served as the loading control. (b) Box-plot analysis of densitometrically quantified Pds5A protein expression. The mean Pds5A expression strengths displayed by LGA and GBM had a statistically significant difference, as determined by a two-tailed t-test (p=0.0116). (c) Percentage of tissue samples expressing Pds5A protein. Light grey columns represent samples with no detectable amounts of protein, grey show weak expression (>0 but <50 on a scale from 0 (no expression detectable) to 100 (strongest expression of ß-tubulin, tumor 2467)) and black columns represent strong expression (≥50).
expression levels, the lung, spleen and cerebrum showed medium expression and the liver, kidney and testes displayed the highest levels of Pds5A mRNA (Fig. 1b). Rat C6 GBM cells, however, had a highly increased Pds5A mRNA expression in comparison to the normal rat organs (Fig. 1).

Pds5A mRNA by rat C6 GBM cells led us to determine whether Pds5A protein could be detected in human GBM cell lines. Our Western blot analysis indicates that the Pds5A protein shows strong expression in U87 cells, medium expression in U343 cells and is weakly but clearly expressed in U251, U373 and GaMG cells (Fig. 2).

To date, human astrocytic tumors have not been analysed for the expression of Pds5A mRNA or protein. Therefore, we screened a panel of 3 NB, 15 LGA and 15 GBM surgical tissue specimens for the expression of both Pds5A mRNA (Fig. 3) and protein (Fig. 4). Pds5A mRNA was detectable in all the samples analysed (Fig. 3a). However, densitometric quantification revealed a statistically significant increase in relative expression strength (ANOVA, p=0.0009) from NB to LGA to GBM (Fig. 3b). In addition, the number of tumors with strong Pds5A mRNA expression also rose (Fig. 3c). We defined the expression strength on a scale from 0 to 100 (zero meaning no expression detectable, 100 representing the strongest Pds5A expression, which was displayed by tumor 2329). Whereas 67% of the NB samples displayed weak expression, 87% of all the GBM samples showed strong Pds5A mRNA expression (weak expression >0 but <50 on our scale and strong expression ≥50) (Fig. 3c). These results were confirmed by Western blotting of the Pds5A protein (Fig. 4). The same tissue samples that were used for RT-PCR analysis were also used for immunoblotting. The relative expression strength was significantly higher in GBM compared to LGA (two-tailed t-test, p=0.0116) (Fig. 4b). There was a high diversity in expression strength between the different glioma samples (Fig. 4a). Whereas there was no Pds5A protein detectable in half of the LGA samples (53%), 73% of the GBM samples exhibited weak (53%) to strong (20%) expression of this protein (Fig. 4c).

Pds5A was expressed in the nuclei of tumor cells in paraffin-embedded GBM sections. We performed immunohistochemistry using paraffin-embedded tissue sections derived from a number of different GBMs. A representative example is shown in Fig. 5. Tissue incubated with appropriate isotype control antibodies served as the negative control (Fig. 5a). Pds5A is a nuclear protein, expressed by ~80% tumor cells. Endothelial cells around blood vessels are not stained. Magnification, 40x. (c) Overview of tumor section. Left, tumor tissue; right, invasion zone. Staining of Pds5A concentrates in tumor tissue. Magnification 10x.

**Figure 5.** Pds5A expression in paraffin-embedded sections of a representative glioblastoma sample. (a-c) Pds5A expression (brown signal) was visualized by staining with a specific antibody. (a) Tissue stained with appropriate isotype control antibodies served as the negative control. Magnification, 40x (b) Nuclear staining of ~80% tumor cells. Endothelial cells around blood vessels are not stained. Magnification, 40x. (c) Overview of tumor section. Left, tumor tissue; right, invasion zone. Staining of Pds5A concentrates in tumor tissue. Magnification 10x.

Pds5A mRNA and protein expressions are up-regulated in human high grade glioma. The high level of expression of

*Pds5A knockdown does not influence mitotic checkpoint function, proliferation and survival of GBM cells.* The data described above indicate that Pds5A plays a role during glioma progression. Therefore, we designed siRNA for specific Pds5A protein knockdown. Transfection of 2 μM siRNA resulted in a markedly reduced Pds5A protein concentration 24 h later. The Pds5A protein concentration constantly remained at a low level for at least 144 h (Fig. 6a).

RNA interference was then used to investigate mitotic checkpoint function in U251 cells by FACS analysis (Fig. 6b). Twenty-four hours after siRNA transfection, nocodazole (25 ng/ml) was added to the cells to interfere with spindle
formation. Whereas the control, the DMSO-treated cells, showed a normal cell cycle profile, the nocodazole-treated cells were arrested in the G2/M phase of the cell cycle, as indicated by the accumulation of 4N cells and the reduction of the 2N peak in the FACS histograms (Fig. 6b). The depletion of Pds5A did not affect the function of the mitotic cell cycle checkpoint, as these cells showed the same FACS profiles as the control cells (Fig. 6b).
Also, the Pds5A knockdown did not influence cell proliferation rates (Fig. 6c). Both U251 cells expressing normal levels of Pds5A protein, and cells depleted of Pds5A, exhibited the same growth rates (Fig. 6c).

An MTT assay was used to measure the metabolic rate and thereby the viability of U251 cells. The arithmetic mean of absorbance at 570 nm for the control medium was 0.27±0.090 (Fig. 6d). Pds5A protein knockdown reduced this...
value to 0.23±0.064. However, this reduction was not statistically significant (Im, p=0.24). In addition, the treatment of U251 cells with 50 μM cisplatin (a DNA-damaging agent), had no effect either in the presence or absence of Pds5A protein expression. On average, the absorbance was 100±7.6% of the control medium. In contrast, the treatment of GBM cells with 100 ng/ml nocodazole caused a significant reduction in absorbance to 73±11% of the DMSO control (Im, p=0.016). However, this was a general nocodazole effect and Pds5A expression did not significantly influence the viability of the cells (Fig. 6d).

Finally, we ascertained whether the Pds5A knockdown induced apoptosis in GBM (GaMG) cells. siRNA-transfected cells were incubated for 72 h with medium and then for another 24 h with 100 ng/ml nocodazole for the induction of the spindle checkpoint and 50 μM cisplatin for DNA-damage induction, respectively. The cells were then analysed for the presence of cleaved caspase-3 by Western blotting (Fig. 6e). The treatment of cells with staurosporine (1 μg/ml for 24 h) induced apoptosis as was assessed by cleaved caspase-3. However, the treatment of the control cells or the Pds5A-depleted cells with either cisplatin or nocodazole did not induce apoptotic cell death in GaMG or U251 cells (data not shown). In all the experiments, the successful depletion of Pds5A was analysed by Western blotting (data not shown).

**Pds5A is required for resolution of sister chromatids.** In order to determine whether Pds5A regulates sister chromatid cohesion, we transfected U251 cells with Pds5A siRNA, which resulted in the efficient depletion of the Pds5A protein (Fig. 7a). The siRNA-treated cells were arrested during mitosis either by treatment with taxol alone or with a combination of taxol and okadaic acid. The mitotically-arrested cells were collected by shake-off and their chromosomes were analysed by spreading and Giemsa staining. Chromosome spreads prepared from taxol-treated, control siRNA-transfected cells displayed the expected X-shaped morphology with resolved sister chromatid arms but were still attached to the centromere (Fig. 7b) (55). However, chromosomes from Pds5A-depleted cells displayed a different morphology (Fig. 7d). Fifteen percent of the chromosome spreads prepared from Pds5A-depleted cells displayed unresolved sister chromatid arms compared to 7% in the control siRNA-treated cells (Fig. 7f). Furthermore, in order to determine whether Pds5A was also required for sister chromatid resolution at the centromere, we treated siRNA-transfected cells with a combination of taxol and okadaic acid (an inhibitor of protein phosphatase type 2A). As expected, in the control siRNA cells, 96% of the chromosomes displayed the complete separation of sister chromatids at both the arms and the centromere (Fig. 7c and g) whereas in the absence of Pds5A, only 79% of the spreads examined displayed complete separation of sisters (Fig. 7e and g). This result suggests that Pds5A is required for sister chromatid separation at both the arms and centromere during mitosis.

**Discussion**

Pds5A is a cohesion complex-interacting protein, which is involved in the establishment, maintenance and dissolution of sister chromatid cohesion (27-30,34,35). Although details about its function remain unresolved, it could also play a role in tumorigenesis (25,26).

Here, we describe the cloning of Pds5A from *Rattus norvegicus* and analyse its expression pattern in rat tissue (Fig. 1). As our initial analysis indicated that levels of Pds5A mRNA were highly elevated in C6 rat GBM cells, we analysed the expression of Pds5A protein in human GBM cell lines by Western blotting (Fig. 2). The high level of expression of Pds5A in human GBM cell lines led us to determine both the Pds5A mRNA and protein expression in patient biopsies of LGA and GBM (Figs. 3 and 4). We found a statistically significant increase in both the Pds5A mRNA and protein levels that correlated positively with the WHO grade of the tumor. Finally, in the paraffin-embedded tissue sections, we observed a high level of nuclear expression of Pds5A in dense tumor tissue and a much weaker expression within the invasion zone (Fig. 5). Our data indicate that Pds5A does not play a role in mitotic checkpoint function and cell proliferation or survival in U251 GBM cells, either with or without the induction of spindle and DNA damage, respectively (Fig. 6). However, our results suggest that Pds5A could regulate sister chromatid cohesion in these cells (Fig. 7).

When we started the cloning of Pds5A, knowledge about its gene structure in *Rattus norvegicus* was based on *in silico* methods and sequence comparisons designed to detect homologies between different species. Therefore, there was only a predicted 3621 bp sequence (GenBank: XM_223406). Our analysis revealed a shift in the boundary between exons 30 and 31, leading to a frameshift and the removal of the originally predicted stop codon in exon 31, thereby extending the coding region of Pds5A to 4001 bp (1333 amino acids). The GenBank sequence, which was updated in the meantime, now confirms our results. As our *Rattus norvegicus* Pds5A cDNA data were based on experimental approaches, the sequence was deposited at NCBI GenBank (EF460313). At the protein level, Pds5A shares 92% identity with its human ortholog, 86% with the *Xenopus laevis* Pds5A and 19% with its ortholog Pdp5p from *S. cerevisiae* (Table I). It has been reported that the human Pds5A shows 23% identity with the *S. cerevisiae* Pdp5p (25). However, the sequence reported by Kumar *et al* (25) lacked several residues at its N-terminus (29) and this could explain why we found only 19% identity between the human and budding yeast protein sequences (Table I). In accordance with previous reports, we found 23% identity between human Pds5A and *Aspergillus nidulans* BimD proteins (40).

**The involvement of Pds5A in mitosis (23-26) implies a broad expression in body tissues.** Indeed, we found the highest expression of Pds5A mRNA in the liver, kidney and testes, all the organs with high rates of cell division, whereas the lung, spleen and cerebrum displayed medium expression. The heart, skeletal muscle and cerebellum had low Pds5A mRNA expression (Fig. 1). In adult mice, high expression of Pds5A mRNA has been reported in the thymus, testis, spleen and lung (36), whereas the brain and kidney displayed intermediate expression and the heart, liver, prostate and stomach, low expression (36). Also, in human organs, Pds5A expression was very broad and is consistent with our data...
zolomide for example, the standard drug used in combination defects introduced by chemotherapeutics (57,58). Temo- adducts (57,58). Therefore, its down-regulation is negatively transferase (AGT), a DNA repair enzyme that removes alkyl (57).

involved in the mitotic checkpoint were up-regulated (56). of budding yeast expressing mutated Pds5p, 6 genes survival of GBM cells. In a global transcriptional analysis knockdown by RNA interference could have any influence proliferation.

Therefore, we analysed whether the Pds5A protein knockdown by RNA interference could have any influence on mitotic checkpoint response, proliferation rate or the survival of GBM cells. In a global transcriptional analysis of budding yeast expressing mutated Pds5p, 6 genes involved in the mitotic checkpoint were up-regulated (56). For this reason, our Pds5A knockdown was combined with nocodazole for the obstruction of spindle formation. However, mitotic spindle checkpoint function remained normal (Fig. 6b).

An aspect of GBM is the association of the promoter methylation status of the O2-methylguanine DNA methyltrans- ferase (MGMT) gene with tumor response to chemotherapies (57). MGMT codes for O2-alkylguanine DNA alkyltransferase (AGT), a DNA repair enzyme that removes alkyl adducts (57,58). Therefore, its down-regulation is negatively associated with the capability of GBM cells to repair DNA defects introduced by chemotherapeutics (57,58). Temozolomide for example, the standard drug used in combination with γ-irradiation for the treatment of GBM (48), is a DNA alkylating agent (59). Frequently, such DNA alterations are mutagenic or lead to DNA strand breaks and subsequently to apoptosis (58). A functional AGT is able to repair such defects and thereby allows for the survival of affected cells (58). It has been shown that BimD, Spo76, Pds5x and Pds5p mutants are hypersensitive after exposure to DNA damaging agents (39,41,60), suggesting that the human Pds5A could possibly play a similar role in DNA repair. Therefore, we also included the treatment of GBM cells with cisplatin for the induction of DNA damage in our experiments. Neverthe- less, Pds5A depleted cells did not develop hypersensitivity to the cisplatin-induced DNA damage (Fig. 6d and e).

The mutation of S. cerevisiae Pds5p causes cell death with features characteristic of apoptosis such as the accumu- lation of DNA breaks, the condensation and fragmentation of chromatin, the fragmentation of nuclei and cell size enlarge- ment (56,60). In vertebrate cells, Pds5A overexpression causes either an increase in apoptosis (25) or an enhancement of malignant cell behavior (26), depending on the cell line used. In our experiments, however, we did not see such effects. The proliferation rate did not change (Fig. 6c) and there was neither a decrease in the viability of GBM cells (Fig. 6d) nor an increase in apoptosis 24 h after treatment with nocodazole or cisplatin (Fig. 6e).

The human Pds5B protein, a paralog of Pds5A, originally isolated as androgene shutoff gene 3 (AS3) from LNCaP prostate cancer cell lines (61) and later designated as APRIN, is a chromatin regulator in hormonal differentiation (62). It shares 73% amino acid identity with Pds5A (Table I) and has been shown to be involved in the regulation of proliferative arrest in cancer cells in response to hormones (61,62). It is a putative tumor suppressor (63,64). It has also been reported that Pds5B can functionally compensate for Pds5A loss (36,65). Therefore, the lack of the above-mentioned effects in our knockdown experiments could be due to the activity of Pds5B in these cells.

Our data in this study support earlier observations that Pds5A plays a key role in releasing cohesin from chromosomes and in sister chromatid segregation (Fig. 7) (42,65,66), although the exact mechanism remains unclear. Pds5A could also function during embryonic development (36,67) and tumorigenesis (25,26). In addition, signalling pathways could have some influence on the regulation of Pds5 protein family members. Bioinformatic studies have revealed that Pds5A contains binding domains for Ras, Rho, RhoGEF, phos- phatidylinositol-3 kinase and cyclin (26), suggesting putative regulation by mitogenic signalling pathways. There is evidence that the mitogenic MAPK cascade is functionally important for glioma proliferation (53,68-71). However, whether there is a direct link between mitogenic signalling and the regulation of Pds5A, has not yet been elucidated. Our ongoing research is addressing this question in conjunction with Pds5B function in GBM cells.

In summary, our data show that Pds5A is up-regulated in GBM, correlating with the WHO grade of human malignant glioma. Although studies have suggested a possible role of Pds5A in mitotic cell division control, mitogenic signalling, apoptosis and DNA repair processes, we only observed an effect of Pds5A on sister chromatid cohesion. Nevertheless, Pds5A, in conjunction with Pds5B, which is able to substitute for its loss (36,65), could turn out to be a promising new target to prevent the progression of LGAs to high grade malignancies and to advance our current treatment options for GBM in the future.

Acknowledgements

We thank Thomas Freiman (Neurochirurgische Klinik, Neurozentrum, University Hospital of Freiburg im Breisgau, Germany) for the NB control tissue and Michaela Kapp (University of Würzburg, Department of Gynaecology and Obstetrics, Würzburg, Germany) for technical assistance.
References


